A randomized Phase II Trial report the impact of PD-L1 expression in anti-PD1 immunotherapy with SBRT for metastatic HNSCC, PD-L1 positive patients was associated with higher ORR rates and better OS [26]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.